Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 101

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 101
---
. Unless we otherwise indicate in a prospectus supplement, we will designate the corporate trust office of the debenture
trustee in the City of New York as our sole paying agent for payments with respect to debt securities of each series. We will name in
the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series.
We will maintain a paying agent in each place of payment for the debt securities of a particular series.

All money we pay to a paying
agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities which remains unclaimed
at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the
security thereafter may look only to us for payment thereof.

Governing Law

The indentures and the debt
securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust
Indenture Act is applicable.

Subordination of Subordinated Debt Securities

Our obligations pursuant to
any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain of our other indebtedness
to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of senior indebtedness we may
incur. It also does not limit us from issuing any other secured or unsecured debt.

| 56 |

<div align='center'>DESCRIPTION OF WARRANTS</div>

General

We may issue warrants to purchase
our Ordinary Shares, including Ordinary Shares represented by Depositary Shares, and/or debt securities in one or more series together
with other securities or separately, as described in the applicable prospectus supplement. Below is a description of certain general terms
and provisions of the warrants that we may offer. Particular terms of the warrants will be described in the warrant agreements and the
prospectus supplement relating to the warrants.

The applicable prospectus
supplement will contain, where applicable, the following terms of and other information relating to the warrants:

| · | the specific designation and aggregate number of, and the price at which we will issue, the warrants; |

| · | the currency or currency units in which the offering price, if any, and the exercise price payable; |

| · | the designation, amount and terms of the securities purchasable upon exercise of the warrants; |

| · | if